HRMY

Harmony Biosciences Holdings, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1802665Held by 3 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$868.0M

Net Income FY2025

$159.0M

EPS (Basic, as reported)

$2.76

Net Margin FY2025

18.3%

ROE FY2025

18.2%

Total Equity

$870.0M

Shares Out

58M

Business description

Harmony Biosciences Holdings, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2019–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 6 → 868 +129.1% CAGR

Fiscal yearFY2019⚑FY2020⚑FY2021FY2022FY2023FY2024FY2025

Revenue6160305438582715868

Cost of revenue(2)(28)(56)(83)(121)(157)(198)

Gross profit4132250354461558670

Research & development(70)(19)(30)(71)(76)(146)(190)

Selling & marketing(44)(56)(68)(79)(97)(111)(120)

General & administrative(36)(40)(64)(84)(95)(110)(153)

Total operating expenses(150)(115)(162)(234)(269)(367)(462)

Operating income(146)1788120192191208

Interest expense(7)(29)(24)(19)(24)(17)(15)

Other income (expense), net—(3)0000(1)

Pre-tax income(152)(37)37105173192215

Income tax expense——(3)(77)(45)(46)(56)

Net income(152)(37)35181129145159

EPS — basic($24.07)($2.48)$0.60$3.07$2.17$2.56$2.76

EPS — diluted($24.07)($2.48)$0.58$2.97$2.13$2.51$2.71

Shares outstanding — basic (M)8265859595757

Shares outstanding — diluted (M)8265961605859

⚑ Weighted-average shares changed ×3.25 between FY2019 and FY2020 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×2.23 between FY2020 and FY2021 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.